Skip to main content
PMC home page
Annals of Oncology logoLink to Annals of Oncology
. 2008 May 7;19(9):1634–1638. doi: 10.1093/annonc/mdn182

Biologic features and treatment outcome of secondary acute lymphoblastic leukemia—a review of 101 cases

R Shivakumar 1, W Tan 2, G E Wilding 2, E S Wang 1,3, M Wetzler 1,*
PMCID: PMC2733065  PMID: 18467310

Abstract

Background: Secondary acute lymphoblastic leukemia (sALL) is a rare disease and its biologic features are not well characterized.

Patients and methods: We describe a cohort of seven patients and discuss 94 additional cases from the literature for whom biological parameters were described. Cases with incomplete data were excluded.

Results: Hodgkin's disease (HD) was more common in the 18–59 age group while breast and prostate cancers were prevalent only in the ≥18-year-old patients. The time interval to develop sALL was similar among all age groups but was significantly longer for HD and neuroblastoma primary diagnoses and sALL with complex karyotype. T-cell immunophenotype was more common in the <18 age group. Complete remission was infrequent in the ≥60 age group. The overall survival was poor for all sALL regardless of age, primary diagnoses, cytogenetic subgroups, or immunophenotype. Allogeneic transplantation most probably represents the only chance of cure.

Conclusion: Better identification of prognostic factors to prevent the occurrence of sALL is indicated.

Keywords: acute lymphoblastic leukemia, 11q23 aberrations, secondary neoplasms

Full Text

The Full Text of this article is available as a PDF (77.2 KB).

Acknowledgments

Dr Shivakumar reviewed the literature and wrote the manuscript, Ms Tan and Dr Wilding analyzed the data, Dr Wang reviewed the data and contributed to the manuscript preparation, and Dr Wetzler oversaw the data collection and statistical analyses and contributed to the manuscript preparation.

References

  • 1.Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849. doi: 10.1200/JCO.1999.17.12.3835. [DOI] [PubMed] [Google Scholar]
  • 2.Pagano L, Pulsoni A, Tosti ME, et al. Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol. 1999;106:1037–1040. doi: 10.1046/j.1365-2141.1999.01636.x. [DOI] [PubMed] [Google Scholar]
  • 3.Petit B, Mele L, Rack K, et al. Characteristics of secondary acute lymphoblastic leukemia with L3 morphology in adult patients. Leuk Lymphoma. 2002;43:1599–1604. doi: 10.1080/1042819021000002929. [DOI] [PubMed] [Google Scholar]
  • 4.Boerma EG, van Imhoff GW, Appel IM, et al. Gender and age-related differences in Burkitt lymphoma—epidemiological and clinical data from The Netherlands. Eur J Cancer. 2004;40:2781–2787. doi: 10.1016/j.ejca.2004.09.004. [DOI] [PubMed] [Google Scholar]
  • 5.Stass S, Mirro J, Melvin S, et al. Lineage switch in acute leukemia. Blood. 1984;64:701–706. [PubMed] [Google Scholar]
  • 6.Zuna J, Cave H, Eckert C, et al. Childhood secondary ALL after ALL treatment. Leukemia. 2007;21:1431–1435. doi: 10.1038/sj.leu.2404718. [DOI] [PubMed] [Google Scholar]
  • 7.Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92:1389–1398. doi: 10.3324/haematol.11034. [DOI] [PubMed] [Google Scholar]
  • 8.Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia. 1993;7:1975–1986. [PubMed] [Google Scholar]
  • 9.Imamura J, Miyoshi I. Koeffler HP. p53 in hematologic malignancies. Blood. 1994;84:2412–2421. [PubMed] [Google Scholar]
  • 10.Koike M, Takeuchi S, Park S, et al. Ovarian cancer: loss of heterozygosity frequently occurs in the ATM gene, but structural alterations do not occur in this gene. Oncology. 1999;56:160–163. doi: 10.1159/000011958. [DOI] [PubMed] [Google Scholar]
  • 11.Sherif ZA, Danielsen M. Balanced t(11;15)(q23;q15) in a TP53+/+ breast cancer patient from a Li-Fraumeni syndrome family. Cancer Genet Cytogenet. 2006;168:50–58. doi: 10.1016/j.cancergencyto.2005.12.009. [DOI] [PubMed] [Google Scholar]
  • 12.Hartikainen JM, Tuhkanen H, Kataja V, et al. An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found. Cancer Epidemiol Biomarkers Prev. 2005;14:75–80. [PubMed] [Google Scholar]
  • 13.Nagahata T, Hirano A, Utada Y, et al. Correlation of allelic losses and clinicopathological factors in 504 primary breast cancers. Breast Cancer. 2002;9:208–215. doi: 10.1007/BF02967591. [DOI] [PubMed] [Google Scholar]
  • 14.Carroll WL, Bhojwani D, Min DJ, et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2003:102–131. doi: 10.1182/asheducation-2003.1.102. [DOI] [PubMed] [Google Scholar]
  • 15.Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999;93:3983–3993. [PubMed] [Google Scholar]
  • 16.Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14:2205–2222. doi: 10.1038/sj.leu.2401973. [DOI] [PubMed] [Google Scholar]
  • 17.Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006;43:126–133. doi: 10.1053/j.seminhematol.2006.01.007. [DOI] [PubMed] [Google Scholar]
  • 18.Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer. 2002;2:124–132. doi: 10.1038/nrc722. [DOI] [PubMed] [Google Scholar]
  • 19.Liberzon E, Avigad S, Stark B, et al. Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children. Genes Chromosomes Cancer. 2004;39:161–166. doi: 10.1002/gcc.10306. [DOI] [PubMed] [Google Scholar]
  • 20.Varady E, Deak B, Molnar ZS, et al. Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma. 2001;42:1275–1281. doi: 10.3109/10428190109097752. [DOI] [PubMed] [Google Scholar]
  • 21.Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:4179–4191. doi: 10.1200/JCO.2005.05.029. [DOI] [PubMed] [Google Scholar]
  • 22.Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43–52. doi: 10.1182/blood-2002-11-3343. [DOI] [PubMed] [Google Scholar]
  • 23.Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189–3197. doi: 10.1182/blood-2006-10-051912. [DOI] [PubMed] [Google Scholar]
  • 24.Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007;20:29–37. doi: 10.1016/j.beha.2006.10.006. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Supplementary Data]
mdn182_index.html (768B, html)
mdn182_mdn182suppl_data.doc (39KB, doc)

Articles from Annals of Oncology are provided here courtesy of Oxford University Press

RESOURCES